CO2022002781A2 - Receptores agonistas no peptídicos de somatostatina tipo 5 y usos de los mismos - Google Patents

Receptores agonistas no peptídicos de somatostatina tipo 5 y usos de los mismos

Info

Publication number
CO2022002781A2
CO2022002781A2 CONC2022/0002781A CO2022002781A CO2022002781A2 CO 2022002781 A2 CO2022002781 A2 CO 2022002781A2 CO 2022002781 A CO2022002781 A CO 2022002781A CO 2022002781 A2 CO2022002781 A2 CO 2022002781A2
Authority
CO
Colombia
Prior art keywords
receptor agonists
compounds
somatostatin type
peptide somatostatin
peptide
Prior art date
Application number
CONC2022/0002781A
Other languages
English (en)
Inventor
Jian Zhao
Yunfei Zhu
Shimiao Wang
Mi Chen
Joseph Pontillo
Original Assignee
Crinetics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crinetics Pharmaceuticals Inc filed Critical Crinetics Pharmaceuticals Inc
Publication of CO2022002781A2 publication Critical patent/CO2022002781A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En el presente documento se describen compuestos que son moduladores de somatostatina, métodos para preparar dichos compuestos, composiciones farmacéuticas y medicamentos que comprenden estos compuestos, y métodos para la utilización de dichos compuestos en el tratamiento de afecciones, enfermedades, o trastornos que pueden beneficiarse de la modulación de la actividad de la somatostatina.
CONC2022/0002781A 2019-08-14 2022-03-10 Receptores agonistas no peptídicos de somatostatina tipo 5 y usos de los mismos CO2022002781A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962886764P 2019-08-14 2019-08-14
PCT/US2020/045610 WO2021030262A1 (en) 2019-08-14 2020-08-10 Nonpeptide somatostatin type 5 receptor agonists and uses thereof

Publications (1)

Publication Number Publication Date
CO2022002781A2 true CO2022002781A2 (es) 2022-06-21

Family

ID=74568328

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0002781A CO2022002781A2 (es) 2019-08-14 2022-03-10 Receptores agonistas no peptídicos de somatostatina tipo 5 y usos de los mismos

Country Status (16)

Country Link
US (2) US11479540B2 (es)
EP (1) EP4013748A4 (es)
JP (1) JP2022544055A (es)
KR (1) KR20220047318A (es)
CN (1) CN114585614A (es)
AR (1) AR119753A1 (es)
AU (1) AU2020327950A1 (es)
BR (1) BR112022002683A2 (es)
CA (1) CA3149840A1 (es)
CL (1) CL2022000354A1 (es)
CO (1) CO2022002781A2 (es)
IL (1) IL290479A (es)
MX (1) MX2022001874A (es)
PE (1) PE20221402A1 (es)
WO (1) WO2021030262A1 (es)
ZA (1) ZA202201829B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA51840A (fr) 2018-02-12 2021-05-19 Crinetics Pharmaceuticals Inc Modulateurs de somatostatine et leurs utilisations
US10696689B2 (en) 2018-09-18 2020-06-30 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
CN114585614A (zh) 2019-08-14 2022-06-03 克林提克斯医药股份有限公司 非肽促生长素抑制素5型受体激动剂及其用途
JP2024506716A (ja) * 2021-02-17 2024-02-14 クリネティックス ファーマシューティカルズ，インク． 高インスリン血症の処置のためのソマトスタチン受容体５型アゴニスト
CA3207378A1 (en) 2021-02-17 2022-08-25 Yuxin Zhao Crystalline forms of a somatostatin modulator
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024089668A1 (en) * 2022-10-28 2024-05-02 Basecamp Bio Inc. Somatostatin receptor 2 agonists and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127343A (en) 1996-05-14 2000-10-03 Novo Nordisk A/S Somatostatin agonists and antagonists
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
US20060281764A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
JP2009530276A (ja) 2006-03-13 2009-08-27 メルク エンド カムパニー インコーポレーテッド ソマトスタチンアゴニスト
KR101117931B1 (ko) 2006-08-15 2012-04-12 에프. 호프만-라 로슈 아게 페닐, 피리딘 및 퀴놀린 유도체
EP2211619A1 (en) 2007-10-18 2010-08-04 Merck Sharp & Dohme Corp. Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
WO2009158467A2 (en) * 2008-06-25 2009-12-30 Envivo Pharmaceuticals, Inc. Di-substituted phenyl compounds
GB0818241D0 (en) 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
WO2011027249A2 (en) 2009-09-01 2011-03-10 Pfizer Inc. Benzimidazole derivatives
CA2799414A1 (en) 2010-05-18 2011-11-24 Merck Sharp & Dohme Corp. Spiro isoxazoline compounds as sstr5 antagonists
GB201008290D0 (en) 2010-05-18 2010-06-30 Syngenta Ltd Chemical compounds
EP2871179A4 (en) 2012-07-03 2016-03-16 Ono Pharmaceutical Co CONNECTION WITH AGONISTIC EFFECT ON THE SOMATOSTATIN RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
WO2015046482A1 (ja) 2013-09-30 2015-04-02 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
US10093795B2 (en) 2013-10-02 2018-10-09 Kuraray Co., Ltd. Resin composition, multilayer sheet, packaging material and container
EP3484865B1 (en) 2016-07-14 2022-09-14 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
RU2019124888A (ru) 2017-02-08 2021-03-10 Оно Фармасьютикал Ко., Лтд. Соединение, имеющее агонистическую активность в отношении рецептора соматостатина, и его фармацевтическое применение
EA201992083A1 (ru) 2017-03-16 2020-03-18 Кринетикс Фармасьютикалс, Инк. Модуляторы соматостатина и их применения
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
MA51840A (fr) 2018-02-12 2021-05-19 Crinetics Pharmaceuticals Inc Modulateurs de somatostatine et leurs utilisations
US10696689B2 (en) 2018-09-18 2020-06-30 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
CN114585614A (zh) 2019-08-14 2022-06-03 克林提克斯医药股份有限公司 非肽促生长素抑制素5型受体激动剂及其用途

Also Published As

Publication number Publication date
EP4013748A4 (en) 2023-08-09
JP2022544055A (ja) 2022-10-17
EP4013748A1 (en) 2022-06-22
CN114585614A (zh) 2022-06-03
MX2022001874A (es) 2022-03-11
AR119753A1 (es) 2022-01-12
BR112022002683A2 (pt) 2022-07-05
US20220144802A1 (en) 2022-05-12
AU2020327950A1 (en) 2022-03-17
ZA202201829B (en) 2023-07-26
WO2021030262A1 (en) 2021-02-18
KR20220047318A (ko) 2022-04-15
TW202115008A (zh) 2021-04-16
CL2022000354A1 (es) 2022-10-21
US11479540B2 (en) 2022-10-25
US20210047287A1 (en) 2021-02-18
CA3149840A1 (en) 2021-02-18
PE20221402A1 (es) 2022-09-15
IL290479A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
CO2022002781A2 (es) Receptores agonistas no peptídicos de somatostatina tipo 5 y usos de los mismos
BR112019000692A8 (pt) Moduladores de somatostatina e usos destes
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
GT201600233A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CO2018009068A2 (es) Derivados de indol y azaindol haloalilamina como inhibidores de lisil oxidasas y usos de los mismos
UY37606A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
MX2020004519A (es) Moduladores de la vía de estrés integrada.
CL2019002671A1 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1.
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
NZ757081A (en) Somatostatin modulators and uses thereof
CL2015002529A1 (es) Compuestos de tetrahidropirrolotiazina
CL2022000998A1 (es) Inhibidores de las cinasas raf
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
CR10062A (es) Composiciones y metodos de tratamiento para trastornos del sistema nervioso central
MX2020013085A (es) Antagonistas del receptor de subtipo 2 de melanocortina (mc2r) y usos de los mismos.
CL2019001329A1 (es) Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso.
CO2021014008A2 (es) Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento
EA202091559A1 (ru) Способ получения модуляторов соматостатина
AR061637A1 (es) Composiciones y metodos de tratamiento de trastornos del snc
BR112017017970A2 (pt) composição de fragrância e combinação de fragrâncias
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
DOP2021000071A (es) Compuestos heteroaromáticos como inhibidores de vanina
DOP2021000021A (es) Compuestos heteroaromáticos como inhibidores de vanina
ECSP19066721A (es) Inhibidores duales de magl y faah
BR112022000855A2 (pt) Moduladores de nlrp3